2021 Targeted Therapies of Lung Cancer

New Date! TTLC 2022 is going Virtual!

Due to the evolving situation caused by ongoing concerns of Coronavirus Disease (COVID-19) and the global surge in Omicron cases. The IASLC is transitioning the Targeted Therapies of Lung Cancer meeting to a fully virtual event. Please take note of the new date, February 22-26, 2022.
Learn More
teal and white image with ILCF logo. Logo reads: International Lung Cancer Foundation, Inspiring Hope through Research. Next to the text is a pair of lungs colored teal and navy blue with markings that resemble a globe

ILCN Research Grant Funding Cycle Opens January 14, 2022

Adequate research funding is key to furthering developments in lung cancer treatment. Through partnering with foundations, non-profits, corporations and individual donors, the ILCF provides multiple funding opportunities each year to facilitate scientific advances and save lives.
Learn More and Apply
Orange Lungs on top of blue background with latin american art watermarked on top. Lungs are sitting next to three green hexagons stacked in a curve around the lungs. Several smaller hexagons float out of the bottom left-hand side of the orange lungs.

Thank You for Attending the LALCA Schools of Thoracic Oncology

Registration for the IASLC 2021 LALCA Schools of Thoracic Oncology is ongoing and complimentary. All meeting content is available through February 28, 2022
Learn More
New Date! TTLC 2022 is going Virtual!
ILCN Research Grant Funding Cycle Opens January 14, 2022
Thank You for Attending the LALCA Schools of Thoracic Oncology

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

In Focus

karen_kelly
Press release

Karen L. Kelly, MD named Chief Executive Officer of the International Association for the Study of Lung Cancer

Contact: Chris Martin | IASLC Media Relations | [email protected] The Board of Directors of the International...
Dec 20, 2021
Read more
Lung Cancer Considered Breakthrough Therapies
Podcast

Breakthrough Therapies- NRG1

Dec 28, 2021

THE IASLC ATLAS OF DIAGNOSTIC IMMUNOHISTOCHEMISTRY (IHC)

New Translations of the IASLC IHC Atlas are available! From IHC biochemistry basics to identifying biomarkers, this text provides a comprehensive view of diagnostic IHC in a reader-friendly format.

Access the IHC Atlas
Language Guide page 1

IASLC Language Guide

In line with the IASLC Equity Statement and in step with the ASCO Language of Respect, we are proud to announce the release of the IASLC Language Guide. The guide was established to instill best practices with commonly used phrases related to patient care. The IASLC will be folding the language found in the guide into all aspects of thoracic oncology education, from abstracts to faculty guidelines to podium presentations. 

Download the Language Guide

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.
Explore More

Lung Ambition Alliance

The IASLC has formed an alliance with three other founding organizations to allow scientists, specialists, advocates, and patients to break the barriers limiting progress and double 5-year survival rates of lung cancer by 2025.
Read more

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
15.609
JTO Impact Factor
8K+
Members

Upcoming Meetings & Webinars

View all Upcoming Events
IASLC Meeting
Feb 22 - Feb 26 2022

2022 Targeted Therapies of Lung Cancer Meeting

Open the Site
Joint Event
Mar 30 - Apr 02 2022

2022 European Lung Cancer Congress

IASLC Meeting
Aug 06 - Aug 09 2022

IASLC 2022 World Conference on Lung Cancer | Vienna

CME Accredited
Open the Site
JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option. 

Explore Our Journals